Treatment effects on markers of systemic inflammation. Time course over the 24-week, blinded study period is shown as geometric mean ratio to baseline (90% confidence intervals [CI]) obtained from MMRM analyses for serum hsCRP (A) and circulating total leukocytes (B), neutrophils (C), and monocytes (D) in patients receiving canakinumab (red line) or placebo (blue line). Dotted horizontal line references baseline levels. Baseline median (range) values for canakinumab/placebo, respectively, in counts of 10⁹/L are as follows: total leukocytes 10.7 (range, 3.5-20.0)/9.1 (range, 4.55-18.20); neutrophils 5.5 (range, 1.57-10.42)/5.0 (range, 2.18-11.19); monocytes 0.9 (range, 0.26-2.50)/0.8 (range, 0.24-2.04). Baseline values for hsCRP are found in Table 1. Spaghetti plots (E) show percent change from baseline of hsCRP for individual patients in the 2 treatment groups as indicated.